These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 20703179)

  • 1. Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study.
    Xie SB; Zhu JY; Ying Z; Zeng LJ; Chao M; Lu MQ
    Transplantation; 2010 Oct; 90(7):786-90. PubMed ID: 20703179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
    Faria LC; Gigou M; Roque-Afonso AM; Sebagh M; Roche B; Fallot G; Ferrari TC; Guettier C; Dussaix E; Castaing D; Brechot C; Samuel D
    Gastroenterology; 2008 Jun; 134(7):1890-9; quiz 2155. PubMed ID: 18424269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
    Wong SN; Chu CJ; Wai CT; Howell T; Moore C; Fontana RJ; Lok AS
    Liver Transpl; 2007 Mar; 13(3):374-81. PubMed ID: 17318855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants.
    Caccamo L; Romeo R; Rossi G; Maggioni M; Radice F; Lunghi G; Colombo M; Fassati LR
    Transpl Int; 2005 Feb; 18(2):186-92. PubMed ID: 15691271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation.
    Karademir S; Astarcioğlu H; Akarsu M; Ozkardesler S; Ozzeybek D; Sayiner A; Akan M; Tankurt E; Astarcioğlu I
    Transplant Proc; 2006 Mar; 38(2):579-83. PubMed ID: 16549180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
    Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
    Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation.
    Na GH; Kim DG; Han JH; Kim EY; Lee SH; Hong TH; You YK; Choi JY
    J Gastroenterol Hepatol; 2014 Jan; 29(1):151-6. PubMed ID: 24117684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation.
    Khemichian S; Hsieh MJ; Zhang SR; Limurti J; Kim J; Fong TL
    Dig Dis Sci; 2015 Sep; 60(9):2807-12. PubMed ID: 25939541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
    Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG
    World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients.
    Gao YJ; Zhang M; Jin B; Meng FP; Ma XM; Liu ZW; Su HB; Zhao JM; Li HW
    J Gastroenterol Hepatol; 2014 Mar; 29(3):554-60. PubMed ID: 24117714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver transplantation for hepatitis B-induced liver disease: long-term outcome and effectiveness of antiviral therapy for prevention of recurrent hepatitis B infection.
    Perrakis A; Förtsch T; Del Medico A; Croner RS; Vassos N; Yedibela S; Lohmüller C; Zopf S; Hohenberger W; Müller V
    Transplant Proc; 2013 Jun; 45(5):1953-6. PubMed ID: 23769081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.
    Singer GA; Zielsdorf S; Fleetwood VA; Alvey N; Cohen E; Eswaran S; Shah N; Chan EY; Hertl M; Fayek SA
    Transplant Proc; 2015 Mar; 47(2):478-84. PubMed ID: 25769595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation.
    Tanaka T; Benmousa A; Marquez M; Therapondos G; Renner EL; Lilly LB
    Clin Transplant; 2012; 26(5):E561-9. PubMed ID: 23061767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral treatment for hepatitis B virus recurrence following liver transplantation.
    Lee S; Kwon CH; Moon HH; Kim TS; Roh Y; Song S; Shin M; Kim JM; Park JB; Kim SJ; Joh JW; Lee SK
    Clin Transplant; 2013; 27(5):E597-604. PubMed ID: 24093615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation.
    Dodson SF; de Vera ME; Bonham CA; Geller DA; Rakela J; Fung JJ
    Liver Transpl; 2000 Jul; 6(4):434-9. PubMed ID: 10915164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation.
    Lee EC; Kim SH; Lee SD; Park H; Lee SA; Park SJ
    World J Gastroenterol; 2016 Apr; 22(14):3803-12. PubMed ID: 27076765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
    Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
    J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation.
    Yuefeng M; Weili F; Wenxiang T; Ligang X; Guiling L; Hongwei G; Wencai L; Xiaoguang W; Wei M; Zhongyi F
    Clin Transplant; 2011; 25(4):517-22. PubMed ID: 20560989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation.
    Hu TH; Chen CL; Lin CC; Wang CC; Chiu KW; Yong CC; Liu YW; Eng HL
    Transplantation; 2014 Apr; 97 Suppl 8():S53-9. PubMed ID: 24849836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis in liver transplantation recipients after hepatitis B virus recurrence.
    Sun LY; Zhu ZJ; Qu W; Sun XY; Rao W; Liu Y
    Hepatogastroenterology; 2014 Oct; 61(135):2047-51. PubMed ID: 25713909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.